| ²é¿´: 603 | »Ø¸´: 0 | |||
xxzrbľ³æ (СÓÐÃûÆø)
|
[ÇóÖú]
DNAÐòÁÐÉè¼Æ
|
|
¸ù¾ÝRNAÀ´Éè¼Æ±í´ïµÄDNA¡£ RNAÐòÁУº5¡¯-GGAGA CGCAA CUGGA AUGAA AUGGU GAAGG ACGGG UCCAG GUGUG GCUGC UUCGG CAGUG CAGCU UGUUG AGUAG AGUGU GAGCU CCGUA ACUAG UCGCG UCAC-3¡¯ The primer complimentary to the 5' end (5ʼ-GTA TAA TAC GAC TCA CTA TAG GGA GAC GCA ACT GAA TGA A-3ʼ includes the T7 promoter, while the 3ʼ primer was considerably shorter (5¡ä-GTG ACG CGA CTA GTT ACG GA-3¡ä) and complimentary to the 3ʼ end of the RNA library.²»¶®Õâ·½ÃæµÄ¶«Î÷£¬ÇóÖ¸µ¼¡£ |
» ²ÂÄãϲ»¶
Wnt-C59£ºPORCN°ÐÏò»¯Ñ§Ì½Õ룬WntÐźÅͨ·×è¶Ï»úÖÆÓë¿ÆÑÐÓ¦ÓÃÈ«½âÎö
ÒѾÓÐ0È˻ظ´
Fexaramine£º³¦µÀÏÞÖÆÐÔFXR»¯Ñ§Ì½Õ룬½á¹¹ÌØÕ÷ÓëÐźÅͨ·Ñо¿È«½âÎö
ÒѾÓÐ0È˻ظ´
»¯Ñ§¹¤³Ì¼°¹¤Òµ»¯Ñ§ÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ276È˻ظ´
NVS-STG2£º°ÐÏòSTING¿çĤÓòµÄ·Ö×Ó½ºÀ༤¶¯¼Á£¬½á¹¹ÌØÕ÷Óë¹Ñ¾Û»¯»úÖÆÑо¿È«½âÎö
ÒѾÓÐ0È˻ظ´
DOTA-GPC3ëÄ£¨CAS 3066439-94-6£©£ºË«¹¦ÄÜ·Ö×Ó̽ÕëǰÌåµÄ½á¹¹ÌØÕ÷Óë±ê¼ÇÓ¦ÓýâÎö
ÒѾÓÐ0È˻ظ´
¿ÆÑÐÓà TLR7/8 Ë«¼¤¶¯¼ÁÔõôѡ£¿ÏÖ»õÓëÖÊ¿ØÒªµã
ÒѾÓÐ0È˻ظ´
SEL120-34A HCl£ºCDK8/CDK19¸ßÑ¡ÔñÐÔ¼¤Ã¸ÒÖÖÆ¼Á
ÒѾÓÐ0È˻ظ´
ÇâÑõ»¯¼Ø»î»¯²Ù×÷
ÒѾÓÐ18È˻ظ´
É¢½ð
ÒѾÓÐ68È˻ظ´
ÉúÎïÖʳ¬¼¶µçÈÝÆ÷
ÒѾÓÐ0È˻ظ´









includes the T7 promoter, while the 3ʼ primer was considerably shorter (5¡ä-GTG ACG CGA CTA GTT ACG GA-3¡ä) and complimentary to the 3ʼ end of the RNA library.
»Ø¸´´ËÂ¥